Analyzing the impact of minimally invasive surgical approaches on post-operative outcomes of pneumonectomy and sleeve lobectomy patients.
Lung cancer
pneumonectomy (PN)
sleeve lobectomy (SL)
video-assisted thoracoscopic surgery (VATS)
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
30 May 2023
30 May 2023
Historique:
received:
12
05
2022
accepted:
24
03
2023
medline:
16
6
2023
pubmed:
16
6
2023
entrez:
16
6
2023
Statut:
ppublish
Résumé
Some patients with non-small cell lung cancer (NSCLC) have superior short- and long-term outcomes with sleeve lobectomy rather than pneumonectomy. Originally sleeve lobectomy was reserved for patients with limited pulmonary function, however, the reported superior results allowed sleeve lobectomy to be performed in expanded patient populations. In a further attempt to improve post-operative outcomes surgeons have adopted minimally invasive techniques Minimally invasive approaches have potential benefits to patients such as decreased morbidity and mortality while maintaining the same caliber of oncologic outcomes. We identified patients at our institution who underwent sleeve lobectomy or pneumonectomy to treat NSCLC from 2007 to 2017. We analyzed these groups in respect to 30- and 90-day mortality, complications, local recurrence, and median survival. We included multivariate analysis to determine the impact of a minimally invasive approach, sex, extent of resection, and histology. Differences in mortality were analyzed using the Kaplan-Meier method using the log-rank test to compare the groups. A two-tailed Z test for difference in proportions was done to analyze complications, local recurrence, 30-day and 90-day mortality. A total of 108 patients underwent sleeve lobectomy (n=34) or pneumonectomy (n=74) for treatment of NSCLC with 18 undergoing open pneumonectomy, 56 undergoing video-assisted thoracoscopic surgery (VATS) pneumonectomy, 29 undergoing open sleeve lobectomy, and 5 undergoing VATS sleeve lobectomy. There was no significant difference in 30-day mortality (P=0.064) but there was a difference in 90-day (P=0.007). There was no difference in complication rates (P=0.234) or local recurrence rates (P=0.779). The pneumonectomy patients had a median survival of 23.6 months (95% CI: 3.8-43.4 months). The sleeve lobectomy group had a median survival of 60.7 months (95% CI: 43.3-78.2 months) (P=0.008). On multivariate analysis extent of resection (P<0.001) and tumor stage (P=0.036) were associated with survival. There was no significant difference between the VATS approach and the open surgical approach (P=0.053). When considering patients undergoing surgery for NSCLC sleeve lobectomy resulted in lower 90-day mortality and better 3-year survival compared to patients undergoing PN. Having a sleeve lobectomy rather than a pneumonectomy and having earlier-stage disease lead to significantly improved survival on multivariate analysis. Having a VATS operation leads to a non-inferior post-operative outcome compared to open surgery.
Sections du résumé
Background
UNASSIGNED
Some patients with non-small cell lung cancer (NSCLC) have superior short- and long-term outcomes with sleeve lobectomy rather than pneumonectomy. Originally sleeve lobectomy was reserved for patients with limited pulmonary function, however, the reported superior results allowed sleeve lobectomy to be performed in expanded patient populations. In a further attempt to improve post-operative outcomes surgeons have adopted minimally invasive techniques Minimally invasive approaches have potential benefits to patients such as decreased morbidity and mortality while maintaining the same caliber of oncologic outcomes.
Methods
UNASSIGNED
We identified patients at our institution who underwent sleeve lobectomy or pneumonectomy to treat NSCLC from 2007 to 2017. We analyzed these groups in respect to 30- and 90-day mortality, complications, local recurrence, and median survival. We included multivariate analysis to determine the impact of a minimally invasive approach, sex, extent of resection, and histology. Differences in mortality were analyzed using the Kaplan-Meier method using the log-rank test to compare the groups. A two-tailed Z test for difference in proportions was done to analyze complications, local recurrence, 30-day and 90-day mortality.
Results
UNASSIGNED
A total of 108 patients underwent sleeve lobectomy (n=34) or pneumonectomy (n=74) for treatment of NSCLC with 18 undergoing open pneumonectomy, 56 undergoing video-assisted thoracoscopic surgery (VATS) pneumonectomy, 29 undergoing open sleeve lobectomy, and 5 undergoing VATS sleeve lobectomy. There was no significant difference in 30-day mortality (P=0.064) but there was a difference in 90-day (P=0.007). There was no difference in complication rates (P=0.234) or local recurrence rates (P=0.779). The pneumonectomy patients had a median survival of 23.6 months (95% CI: 3.8-43.4 months). The sleeve lobectomy group had a median survival of 60.7 months (95% CI: 43.3-78.2 months) (P=0.008). On multivariate analysis extent of resection (P<0.001) and tumor stage (P=0.036) were associated with survival. There was no significant difference between the VATS approach and the open surgical approach (P=0.053).
Conclusions
UNASSIGNED
When considering patients undergoing surgery for NSCLC sleeve lobectomy resulted in lower 90-day mortality and better 3-year survival compared to patients undergoing PN. Having a sleeve lobectomy rather than a pneumonectomy and having earlier-stage disease lead to significantly improved survival on multivariate analysis. Having a VATS operation leads to a non-inferior post-operative outcome compared to open surgery.
Identifiants
pubmed: 37324102
doi: 10.21037/jtd-22-654
pii: jtd-15-05-2497
pmc: PMC10267906
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2497-2504Commentaires et corrections
Type : CommentIn
Informations de copyright
2023 Journal of Thoracic Disease. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-654/coif). The authors have no conflicts of interest to declare.
Références
Kardiochir Torakochirurgia Pol. 2019 Mar;16(1):7-12
pubmed: 31043969
Thorac Cancer. 2014 Nov;5(6):494-9
pubmed: 26767043
Ann Thorac Surg. 2005 Mar;79(3):968-73
pubmed: 15734415
Turk Gogus Kalp Damar Cerrahisi Derg. 2019 Jan 01;27(1):93-100
pubmed: 32082833
J Thorac Oncol. 2013 May;8(5):637-43
pubmed: 23584296
Ann Thorac Surg. 2006 Feb;81(2):421-5; discussion 425-6
pubmed: 16427825
J Thorac Dis. 2016 Nov;8(Suppl 11):S872-S881
pubmed: 27942409
J Vis Surg. 2017 Mar 17;3:32
pubmed: 29078595
Ann Thorac Surg. 2012 Apr;93(4):1027-32
pubmed: 22130269
Surg Laparosc Endosc. 1992 Sep;2(3):244-7
pubmed: 1341539
J Cancer. 2017 Jul 5;8(11):2097-2103
pubmed: 28819411
Semin Thorac Cardiovasc Surg. 2021 Summer;33(2):522-530
pubmed: 32858216
J Thorac Cardiovasc Surg. 2021 Dec;162(6):1619-1628.e4
pubmed: 32919775
Chest. 2002 Feb;121(2):635-6
pubmed: 11834681
J Thorac Dis. 2015 Oct;7(10):1742-8
pubmed: 26623096
J Thorac Cardiovasc Surg. 2019 Aug;158(2):570-578.e3
pubmed: 31056356
J Thorac Oncol. 2010 Apr;5(4):517-20
pubmed: 20104190
Am Fam Physician. 2007 Jan 1;75(1):56-63
pubmed: 17225705
Ann Thorac Surg. 2005 Dec;80(6):2046-50
pubmed: 16305842
Ann Thorac Surg. 2015 Feb;99(2):399-405
pubmed: 25499481
Interact Cardiovasc Thorac Surg. 2010 Nov;11(5):660-6
pubmed: 20724429
Ann Thorac Surg. 2003 Dec;76(6):1782-8
pubmed: 14667584
Thorax. 1995 Apr;50(4):392-5
pubmed: 7785013
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
J Thorac Cardiovasc Surg. 2003 Dec;126(6):2083-5
pubmed: 14688732
Ann Thorac Surg. 2010 Jun;89(6):S2098-101
pubmed: 20493989
J Thorac Dis. 2020 Oct;12(10):5678-5690
pubmed: 33209400
Ann Thorac Surg. 2017 Nov;104(5):1656-1664
pubmed: 28935348
J Vis Surg. 2017 Mar 31;3:41
pubmed: 29078604
Ann Thorac Surg. 2006 Jul;82(1):e3-4
pubmed: 16798175
J Thorac Dis. 2016 Jun;8(6):1227-33
pubmed: 27293841
Interact Cardiovasc Thorac Surg. 2008 Dec;7(6):986-9
pubmed: 18603544
Ann Thorac Surg. 2019 Oct;108(4):1072-1079
pubmed: 31163131